Amylyx Pharmaceuticals
AMLX
178 hedge funds and large institutions have $929M invested in Amylyx Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 78 increasing their positions, 46 reducing their positions, and 28 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 46
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
6.02% more ownership
Funds ownership: 87.46% → 93.47% (+6%)
5% more funds holding
Funds holding: 170 → 178 (+8)
1% more call options, than puts
Call options by funds: $50.9M | Put options by funds: $50.4M
14% less capital invested
Capital invested by funds: $1.08B → $929M (-$150M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$72.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$42.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$15.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.3M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$38.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$31.1M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$25.9M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$23.1M |
| 5 |
SC
Samlyn Capital
New York
|
-$21.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
201
Prelude Capital Management
New York
| – | -$304K | -16,600 | Closed |
|
|
WMSA
202
Weiss Multi-Strategy Advisers
New York
| – | -$257K | -14,054 | Closed |
|
|
AC
203
AXQ Capital
Jersey City,
New Jersey
| – | -$198K | -10,836 | Closed |
|
204
Credit Agricole
Montrouge Cedex,
France
| – | -$9.15K | -500 | Closed |
|
|
TWM
205
Tradition Wealth Management
Edina,
Minnesota
| – | -$9K | -500 | Closed |
|
|
AF
206
Allworth Financial
Folsom,
California
| – | -$1.83K | -100 | Closed |
|
AMLX Hedge Fund Activity: Q4 2023 in Review
178 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q4 2023, worth a combined $929M — down 14% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AMLX positions and 28 closed out — a net gain of 9 holders — while 78 added to existing stakes and 46 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $72.2M. The largest seller was Boxer Capital, exiting entirely with an estimated $38.2M sold.
- 178 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q4 2023, up from 170 in Q3 2023.
- Funds reported $929M of Amylyx Pharmaceuticals stock for Q4 2023, down 14% quarter-over-quarter.
- 37 funds opened new Amylyx Pharmaceuticals positions in Q4 2023 and 28 closed out, a net change of +9 holders.
- The largest Amylyx Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $72.2M added.
- The largest Amylyx Pharmaceuticals seller in Q4 2023 was Boxer Capital, an estimated $38.2M sold.
Based on aggregated 13F filings for Q4 2023.